Reximmune-C
Alternative Names: Reximmune-CLatest Information Update: 14 Sep 2015
At a glance
- Originator Epeius Biotechnologies
- Developer Epeius Biotechnologies Corporation
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer